 Karnofsky Performance Status
"Karnofsky Performance Status" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A performance measure for rating the ability of a person to perform usual activities, evaluating a patient's progress after a therapeutic procedure, and determining a patient's suitability for therapy. It is used most commonly in the prognosis of cancer therapy, usually after chemotherapy and customarily administered before and after therapy. It was named for Dr. David A. Karnofsky, an American specialist in cancer chemotherapy.
| Descriptor ID |
D017567
|
| MeSH Number(s) |
E05.318.308.980.438.475.456.500.500 N05.715.360.300.800.438.375.364.500.500 N06.850.520.308.980.438.475.364.500.500
|
| Concept/Terms |
Karnofsky Performance Status- Karnofsky Performance Status
- Performance Status, Karnofsky
- Status, Karnofsky Performance
- Karnofsky Performance Status Scale
- Karnofsky Scale
- Scale, Karnofsky
- Karnofsky Index
- Index, Karnofsky
|
Below are MeSH descriptors whose meaning is more general than "Karnofsky Performance Status".
Below are MeSH descriptors whose meaning is more specific than "Karnofsky Performance Status".
This graph shows the total number of publications written about "Karnofsky Performance Status" by people in this website by year, and whether "Karnofsky Performance Status" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1998 | 0 | 1 | 1 | | 2000 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2006 | 1 | 0 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 2 | 2 | | 2011 | 0 | 2 | 2 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2016 | 1 | 2 | 3 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 2 | 2 | | 2019 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Karnofsky Performance Status" by people in Profiles.
-
Ge H, Di G, Yan Z, Liu D, Liu Y, Song K, Yang K, Hu X, Jiang Z, Hu X, Tian L, Xiao C, Zou Y, Liu H, Chen J. Does epilepsy always indicate worse outcomes? A longitudinal follow-up analysis of 485 glioma patients. World J Surg Oncol. 2022 Sep 19; 20(1):297.
-
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, Lee J, Kirkpatrick JP, Breen W, Brown PD, Shi D, Shih HA, Soliman H, Sahgal A, Shanley R, Sperduto WA, Lou E, Everett A, Boggs DH, Masucci L, Roberge D, Remick J, Plichta K, Buatti JM, Jain S, Gaspar LE, Wu CC, Wang TJC, Bryant J, Chuong M, An Y, Chiang V, Nakano T, Aoyama H, Mehta MP. Survival in Patients With Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient. J Clin Oncol. 2020 11 10; 38(32):3773-3784.
-
Mei G, Liu X, Song K, Lv Y, Xu M, Xu H, Wang E. Cyberknife radiosurgery on the brainstem metastases of non-small cell lung cancer. Int J Neurosci. 2021 May; 131(5):462-467.
-
Lareau SC, Blackstock FC. Functional status measures for the COPD patient: A practical categorization. Chron Respir Dis. 2019 Jan-Dec; 16:1479973118816464.
-
Franko LR, Hollon T, Linzey J, Roark C, Rajajee V, Sheehan K, Teig M, Hervey-Jumper S, Heth J, Orringer D, Williamson CA. Clinical Factors Associated With ICU-Specific Care Following Supratentoral Brain Tumor Resection and Validation of a Risk Prediction Score. Crit Care Med. 2018 08; 46(8):1302-1308.
-
Goey KKH, S?rbye H, Glimelius B, Adams RA, Andr? T, Arnold D, Berlin JD, Bodoky G, de Gramont A, D?az-Rubio E, Eng C, Falcone A, Grothey A, Heinemann V, Hochster HS, Kaplan RS, Kopetz S, Labianca R, Lieu CH, Meropol NJ, Price TJ, Schilsky RL, Schmoll HJ, Shacham-Shmueli E, Shi Q, Sobrero AF, Souglakos J, Van Cutsem E, Zalcberg J, van Oijen MGH, Punt CJA, Koopman M. Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. Eur J Cancer. 2018 09; 100:35-45.
-
Sperduto PW, Jiang W, Brown PD, Braunstein S, Sneed P, Wattson DA, Shih HA, Bangdiwala A, Shanley R, Lockney NA, Beal K, Lou E, Amatruda T, Sperduto WA, Kirkpatrick JP, Yeh N, Gaspar LE, Molitoris JK, Masucci L, Roberge D, Yu J, Chiang V, Mehta M. Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):812-816.
-
Bunn PA. Karnofsky Award 2016: A Lung Cancer Journey, 1973 to 2016. J Clin Oncol. 2017 01 10; 35(2):243-252.
-
Randolph TC, Simon DN, Thomas L, Allen LA, Fonarow GC, Gersh BJ, Kowey PR, Reiffel JA, Naccarelli GV, Chan PS, Spertus JA, Peterson ED, Piccini JP. Patient factors associated with quality of life in atrial fibrillation. Am Heart J. 2016 Dec; 182:135-143.
-
Wang TJ, Jani A, Estrada JP, Ung TH, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Isaacson SR, Cheng SK, McKhann GM, Bruce JN, Lassman AB, Sisti MB. Timing of Adjuvant Radiotherapy in Glioblastoma Patients: A Single-Institution Experience With More Than 400 Patients. Neurosurgery. 2016 May; 78(5):676-82.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|